



A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications

Jennifer A. Frontera^{*}, Dixon Yang, Ariane Lewis, Palak Patel, Chaitanya Medicherla, Vito Arena, Taolin Fang, Andres Andino, Thomas Snyder, Maya Madhavan, Daniel Gratch, Benjamin Fuchs, Alexa Dessy, Melanie Canizares, Ruben Jauregui, Betsy Thomas, Kristie Bauman, Anlys Olivera, Dhristie Bhagat, Michael Sonson, George Park, Rebecca Stainman, Brian Sunwoo, Daniel Talmasov, Michael Tamimi, Yingrong Zhu, Jonathan Rosenthal, Levi Dygert, Milan Ristic, Haruki Ishii, Eduard Valdes, Mirza Omari, Lindsey Gurin, Joshua Huang, Barry M. Czeisler, D. Ethan Kahn, Ting Zhou, Jessica Lin, Aaron S. Lord, Kara Melmed, Sharon Meropol, Andrea B. Troxel, Eva Petkova, Thomas Wisniewski, Laura Balcer, Chris Morrison, Shadi Yaghi, Steven Galetta

New York University Grossman School of Medicine, New York, NY, USA

ARTICLE INFO

Keywords:

Post-acute sequelae of COVID
Post-COVID syndrome
Long-hauler
Long-COVID
COVID-19
SARS-CoV-2
Outcomes
Cognitive
Quality of life
Readmission
Neurologic
Brain
Function
Anxiety
Depression
Fatigue
Sleep

ABSTRACT

Background: Little is known regarding long-term outcomes of patients hospitalized with COVID-19.

Methods: We conducted a prospective study of 6-month outcomes of hospitalized COVID-19 patients. Patients with new neurological complications during hospitalization who survived were propensity score-matched to COVID-19 survivors without neurological complications hospitalized during the same period. The primary 6-month outcome was multivariable ordinal analysis of the modified Rankin Scale(mRS) comparing patients with or without neurological complications. Secondary outcomes included: activities of daily living (ADLs; Barthel Index), telephone Montreal Cognitive Assessment and Neuro-QoL batteries for anxiety, depression, fatigue and sleep.

Results: Of 606 COVID-19 patients with neurological complications, 395 survived hospitalization and were matched to 395 controls; $N = 196$ neurological patients and $N = 186$ controls completed follow-up. Overall, 346/382 (91%) patients had at least one abnormal outcome: 56% had limited ADLs, 50% impaired cognition, 47% could not return to work and 62% scored worse than average on ≥ 1 Neuro-QoL scale (worse anxiety 46%, sleep 38%, fatigue 36%, and depression 25%). In multivariable analysis, patients with neurological complications had worse 6-month mRS (median 4 vs. 3 among controls, adjusted OR 1.98, 95%CI 1.23–3.48, $P = 0.02$), worse ADLs (aOR 0.38, 95%CI 0.29–0.74, $P = 0.01$) and were less likely to return to work than controls (41% versus 64%, $P = 0.04$). Cognitive and Neuro-QoL metrics were similar between groups.

Conclusions: Abnormalities in functional outcomes, ADLs, anxiety, depression and sleep occurred in over 90% of patients 6-months after hospitalization for COVID-19. In multivariable analysis, patients with neurological complications during index hospitalization had significantly worse 6-month functional outcomes than those without.

1. Introduction

Acute neurological complications of hospitalized COVID-19 patients have been described in several cohorts worldwide [1–9], however,

limited data exists regarding long-term cognitive and functional outcomes. Reports of prolonged memory disorders, fatigue, and persistent respiratory symptoms have been grouped together in the rubric of “Post COVID syndrome” or “Post-acute sequelae of COVID” [10], yet little is

^{*} Corresponding author at: NYU Department of Neurology, 150 55th St., Brooklyn, NY 11220, USA.

E-mail address: jennifer.frontera@nyulangone.org (J.A. Frontera).

<https://doi.org/10.1016/j.jns.2021.117486>

Received 25 February 2021; Received in revised form 15 April 2021; Accepted 10 May 2021

Available online 12 May 2021

0022-510X/© 2021 Elsevier B.V. All rights reserved.

known regarding the prevalence, risk factors or pathophysiology behind this group of symptoms.

Recently, we reported on a prospective cohort of 4491 COVID-19 patients hospitalized during the spring 2020 surge in New York City and identified 606 (14%) with new neurological disorders during hospitalization [11]. In this study, we followed this initial cohort longitudinally for 6-months to evaluate longer-term outcomes. Our primary aim was to compare global functional outcomes between COVID-19 hospital survivors with and without neurological complications using an ordinal analysis of the modified Rankins Scale (mRS). Secondary outcomes included assessments of activities of daily living, return to work, cognitive function, anxiety, depression, fatigue and sleep abnormalities. We hypothesized that long-term functional outcomes would be worse among patients with neurological complications compared to age, gender and severity of illness-matched COVID-19 controls without neurological complications.

2. Methods

2.1. Study design and patient cohort

We conducted a prospective, observational study of consecutive COVID-19 patients hospitalized at four New York City area hospitals within the same hospital system between March 10, 2020 and May 20, 2020. Patients with new neurological complications during index hospitalization who survived were propensity score-matched to COVID-19 survivors *without* neurological complications hospitalized during the same period and 6-month follow-up interviews were performed. Inclusion criteria were: age ≥ 18 years, hospital admission, reverse-transcriptase-polymerase-chain-reaction (RT-PCR) positive SARS-CoV-2 infection from nasopharyngeal sampling, survival to discharge and consent to participate in a follow-up interview. Exclusion criteria were: negative or missing SARS-CoV-2 RT-PCR test, or evaluation in an outpatient or emergency department setting only. Only index admissions were included; readmissions were excluded to avoid double counting.

Patients were prospectively screened following hospital admission according to previously published criteria [11]. Briefly, initial screening for inclusion was performed by the emergency department or admitting team, wherein a neurology consult would be triggered according to routine protocol for patients with new or worsened neurological disorders. Next, all inpatients evaluated by an in-hospital neurologist were screened twice daily for study inclusion and data abstraction was performed by neurology attendings, residents and fellows. COVID-19 patients who were prospectively excluded due to “no new neurological disorder” after evaluation by a neurologist were eligible for inclusion in the control group.

2.2. Neurological diagnoses and severity of illness scales

Neurological diagnoses—including toxic-metabolic encephalopathy, hypoxic-ischemic encephalopathy, stroke (ischemic or hemorrhagic), seizure, neuropathy, myopathy, movement disorder, encephalitis/meningitis, myelopathy, myelitis—followed established criteria [12–21] and were coded for COVID-19 patients found to have a *new* neurological complication (excluding recrudescence or worsening of old neurological deficits) as diagnosed by in-hospital neurology teams. A second review of neurological diagnoses was performed by relevant subspecialty co-authors (e.g. stroke, neurocritical care, epilepsy sub-specialists). Patients could be coded for more than one neurological complication.

Demographic data, past medical history, clinical course and hospital outcomes (mortality rates discharge disposition, ventilator days and hospital length of stay) were collected. Severity of illness during hospitalization was assessed using both the maximum recorded Sequential Organ Failure Assessment (SOFA) score, and the lung severity scale [22] for hospitalized patients (0 = no oxygen requirement, 1 = supplemental

oxygen required, 2 = high-flow nasal cannula or non-invasive ventilation, 3 = invasive mechanical ventilation). Past medical history data was gathered through review of the medical record. A past history of dementia was coded for patients with pre-existing diagnoses of mild cognitive impairment, Alzheimer's type dementia, vascular dementia, Lewy body/Parkinson's related dementia, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, frontal-temporal dementia, normal pressure hydrocephalus or Creutzfeldt-Jakob disease. Pre-morbid baseline mRS were collected based on patient/surrogate report.

2.3. Study outcomes

Longitudinal 6-month follow-up assessments were conducted by telephone interview among case and control hospital survivors or their surrogates who consented to participate. Contact was attempted at 6-months (± 1 month) from the onset of neurological symptoms among cases, or from the onset of COVID-19 symptoms among controls. Based on prior data, the median time from general COVID-19 symptom onset to neurological complication was 2 days [11]. Three attempts at contact were required before patients/surrogates were coded as “unreachable”.

We selected outcome measures that could be assessed via telephone interview, were validated for completion by surrogates, and could be completed in approximately 30 min to avoid participant fatigue. The primary outcome was the modified Rankin Scale [mRS; 0 = no symptoms, 6 = dead] [23], analyzed using an ordinal proportional odds model. Secondary outcomes included: the Barthel Index [24] for activities of daily living (0 = completely dependent, 100 = independent for all activities), the Telephone Montreal Cognitive Assessment (MoCA; 22 = perfect score; ≤ 18 = abnormal cognition) [25], and Quality of Life in Neurological Disorders [26] (Neuro-QoL) short form self-reported health measures of anxiety, depression, fatigue and sleep. Patients with fewer than 13 years of education received an additional point when scoring the telephone MOCA [27]. The outcomes of occurrence of return to work among those employed pre-morbidly and hospital readmission were self-reported by the patient or their surrogate. Patients were coded as having “returned to work” if they resumed work either in person or remotely, even if they changed employers. All of the above batteries have been validated for surrogate completion with the exception of the telephone MoCA, which was only scored if the patient was able to complete the assessment. Incomplete or partial responses to a given metric were excluded from analysis.

2.4. Standard protocol approvals and patient consents

This study was approved by the NYU Grossman School of Medicine Institutional Review Board. All patients or their surrogates provided consent for participation.

2.5. Statistical analyses

Controls (COVID-19 patients *without* neurological complications during index hospitalization) were propensity score matched 1:1 to cases (COVID-19 patients *with* neurological complications) by age, gender and intubation status (as a marker of illness severity during index hospitalization) using a matching ratio of 0.01, random order drawing of matches, without replacement and with priority given to exact matches. These variables were selected for matching as they differed significantly in the parent cohort. Additional differences between groups were adjusted for in multivariable regression analyses. Demographic variables, past medical history, clinical course and in-hospital outcomes were compared between COVID-19 patients with and without a new neurological event using the Mann-Whitney *U* test for non-normally distributed continuous variables and Chi-square test for categorical values, as appropriate. Neuro-QoL raw scores were converted into T-scores with a mean of 50 and standard deviation of 10 in a reference

population (U.S. general population or clinical sample) [28]. Higher T-scores indicate worse self-reported health for the anxiety, depression, fatigue and sleep metrics. Secondary outcomes were dichotomized based on clinically relevant or published thresholds. For patients who died, a mRS score of 6 was assigned, but no other outcome variables were scored.

Ordinal logistic regression models predicting 6-month mRS were constructed to determine the effect of neurological complications during COVID-19 hospitalization. Secondary outcomes were compared between those with or without neurological disorders using Mann-Whitney U (Wilcoxon rank-sum) or Chi-squared tests as appropriate. Variables (demographics, past medical history, clinical course) predictive of mRS scores in univariate analysis with a P value ≤ 0.100 were entered into multivariable ordinal logistic regression analysis to estimate the adjusted odds ratios (aOR) and 95% confidence intervals (CI) for the primary outcome of mRS score. Clinically relevant interactions were tested. Additionally, multivariable, backward step-wise, binary logistic regression models were constructed predicting dichotomized secondary outcomes of Barthel Index (fully independent versus any abnormal ADLs), MoCA (abnormal score ≤ 18 versus >18 [25]), Neuro-QoL T-scores worse than average (>50) and return to work, including univariate predictors with a P -value ≤ 0.100 . Tests for collinearity and multicollinearity were conducted using correlation coefficients, variance inflation factor and tolerance statistic testing. Correlations between different outcome measures were assessed using Spearman correlation coefficients. All analyses were conducted using IBM SPSS Statistics for Mac version 26 (IBM Corp., Armonk, NY).

3. Results

Of 606 hospitalized COVID-19 patients prospectively identified with new neurological complications, 395 (65%) survived to hospital discharge [11]. Among the 3885 COVID-19 control patients without neurological complications hospitalized during the same time frame, 3134 (81%) survived and 395 were propensity-score matched by age, gender and ventilator status to the surviving neurological patients (Supplemental Table 1). Seven-hundred-ninety follow-up calls were attempted at 6-months, and 382 ($N = 196$ neurological cases and $N = 186$ controls) were completed (Fig. 1). The median age of patients with neurological complications was 68 years compared to 69 years for those without neurological events ($P = 0.388$). The two propensity-score matched groups were also similar in gender (65% were male in both groups, $P = 0.872$), race/ethnicity and intubation status (34% were

intubated in each group, $P = 0.880$, Table 1). The median time from first COVID-19 symptom (e.g. fever, cough, nausea, vomiting, diarrhea) to neurologic complication onset was 2 days (interquartile range [IQR] 0–13). The median time from neurological symptom onset (or COVID-19 symptom onset for controls) to follow-up interview was 6.7 (IQR 6.5–6.8) months. Between discharge and 6-months, 40/196 (20%) neurological patients and 35/186 (19%) controls died ($P = 0.715$) in a median of 0.8 (IQR 0.4–2.1) months from symptom onset. Among those able to participate in outcome assessments, direct responses were obtained from 121/156 (78%) neurological patients and 131/151 (87%) controls, while surrogate responses were utilized in 35/156 (22%) neurological patients and 20/151 (13%) controls ($P = 0.026$).

3.1. Cohort descriptors

Among the neurological cohort, the most common diagnoses were toxic-metabolic encephalopathy (52%), hypoxic-ischemic encephalopathy (21%), stroke (11%), and seizure (11%, Table 1). Compared to control patients, neurological patients had lower body mass indices, more past history of dementia, stroke and seizure, worse SOFA scores during hospitalization and higher rates of acute renal failure (all $P < 0.05$, Table 1). Patients with newly diagnosed neurological events were more often discharged to a nursing home and less often discharged home than control patients. In the entire cohort, 346/382 (91%) patients had at least one abnormal outcome at 6-months: 170/304 (56%) had limited activities of daily living (Barthel(100), 106/215 (50%) had impaired cognition (telephone MOCA <18), the median mRS was 3 (IQR 1–5), 47% (81/154) of those working pre-morbidly were unable to return to work at 6-months. Of those able to complete the Neuro-QoL batteries, 174/280 (62%) demonstrated worse than average scores compared to reference populations (T-score > 50) on at least one metric: 128/280 (46%) scored worse than average on anxiety; 105/278 (38%) on sleep; 98/272 (36%) on fatigue, and 71/279 (25%) on depression.

3.2. Primary outcome (modified Rankin Score)

Six-month mRS scores were significantly worse in patients with neurological complications (median 4, IQR 2–5) compared to controls (median 3, IQR 1–4, unadjusted ordinal logistic regression analysis OR 1.57, 95% CI 1.10–2.24, Wald $\chi^2(1) = 6.096$, $P = 0.014$; Fig. 2). Univariate predictors of 6-month outcomes, including demographics, past medical history, hospital course, specific neurological diagnoses, and COVID-19 specific medications are listed in Supplemental Table 2.




Fig. 1. Flow chart of case and control inclusion and exclusion.

Table 1

Comparison of COVID-19 patients with and without neurological disorders during hospitalization.

Characteristic	Neurologic COVID-19 N = 196	COVID-19 Control N = 186	P
Demographics			
Median Age (IQR)-yr	68 (55–77)	69 (57–78)	0.388
Male sex-no./total no. (%)	128/196 (65%)	120/186 (65%)	0.872
Body Mass Index-median (IQR)*	26 (23–30)	28 (24–35)	0.004
Race- no./total no. (%)			
White	86/196 (44%)	77/186 (41%)	0.245
Black	22/196 (11%)	26/186 (14%)	
Asian	20/196 (10%)	8/186 (4%)	
Native American/Pacific Islander	1/196 (0.5%)	1/186 (1%)	
American Indian	1/196 (0.5%)	1/186 (1%)	
Ethnicity- no./total no. (%)			
Hispanic	30/196 (15%)	40/186 (22%)	0.274
Non-Hispanic	122/196 (62%)	110/186 (59%)	
Prefer not to answer	44/196 (23%)	36/186 (19%)	
Past Medical History- no./total no. (%)			
Dementia*	28/196 (14%)	11/186 (6%)	0.016
Psychiatric Illness	32/196 (16%)	16/186 (9%)	0.075
Stroke (ischemic or hemorrhagic)*	40/196 (20%)	17/186 (9%)	0.002
Seizure*	32/196 (16%)	7/186 (4%)	<0.001
Movement Disorder	5/196 (3%)	1/186 (0.5%)	0.171
Multiple sclerosis/demyelinating disease	0	3/186 (2%)	0.119
Chronic kidney disease	33/196 (17%)	18/186 (10%)	0.074
Hypertension	78/196 (40%)	87/186 (47%)	0.214
Diabetes	62/196 (32%)	48/186 (26%)	0.279
Coronary artery disease	36/196 (18%)	33/186 (18%)	0.584
COPD/Asthma	17/196 (9%)	21/186 (11%)	0.403
Atrial Fibrillation	28/196 (14%)	17/186 (9%)	0.128
Venous thromboembolism*	22/196 (11%)	11/186 (6%)	0.07
Baseline modified Rankin Score-median (range)	0 (0–5)	0 (0–5)	0.481
Hospital course			
Date of Admission -median (IQR)	4/3/2020 (3/28/2020–4/10/2020)	4/2/2020 (3/25/2020–4/11/2020)	0.399
Hospital Location			
Brooklyn	45/196 (23%)	55/186 (30%)	0.081
Manhattan, midtown	71/196 (36%)	50/186 (27%)	
Manhattan, downtown	23/196 (12%)	15/186 (8%)	
Mineola, Long Island	57/196 (29%)	66/186 (35%)	
Intensive care unit vs. non-ICU unit- no./total no. (%)	69/196 (35%)	54/186 (29%)	0.223
Intubation- no./total no. (%)	66/196 (34%)	64/186 (34%)	0.880
Worst SOFA score- median (IQR)*	4 (3–10)	4 (3–6)	0.044
Lowest Oxygen saturation (%), median (IQR)	88% (74–92%)	88% (78–91%)	0.931
Lowest Mean Arterial Pressure (mmHg), median (IQR)	63 (52–72)	65 (54–73)	0.161
Acute renal failure- no./total no. (%)*	43/196 (22%)	23/186 (12%)	0.014
Hypotension requiring vasopressors- no./total no. (%)	58/196 (30%)	43/186 (23%)	0.152
Neurological disorders during hospitalization			
Toxic/Metabolic	102 (52%)	–	–
Encephalopathy- no./total no. (%)	–	–	–
Stroke (any type) - no./total no. (%)	21 (11%)	–	–
Ischemic/TIA	15 (8%)	–	–
Intracerebral/Intraventricular hemorrhage	6 (3%)	–	–
Spontaneous Subarachnoid hemorrhage	0	–	–

Table 1 (continued)

Characteristic	Neurologic COVID-19 N = 196	COVID-19 Control N = 186	P
Seizure (clinical or electrographic) - no./total no. (%)	21 (11%)	–	–
Hypoxic/ischemic brain injury- no./total no. (%)	42 (21%)	–	–
Movement Disorder- no./total no. (%)	15 (8%)	–	–
Neuropathy- no./total no. (%)	15 (8%)	–	–
Myopathy- no./total no. (%)	7 (4%)	–	–
Guillain Barre Syndrome- no./total no. (%)	3 (1.5%)	–	–
Encephalitis/meningitis- no./total no. (%)	0	–	–
Myelopathy/Myelitis- no./total no. (%)	0	–	–
Medications during hospitalization			
Corticosteroids- no./total no. (%)	49/196 (25%)	52/186 (28%)	0.512
Hydroxychloroquine- no./total no. (%)	138/196 (70%)	134/186 (72%)	0.724
Azithromycin- no./total no. (%)	121/196 (62%)	125/196 (67%)	0.264
Remdesivir- no./total no. (%)	0	1/186 (0.5%)	0.304
Therapeutic anticoagulation- no./total no. (%)	75/196 (38%)	59/186 (32%)	0.180
Tocilizumab- no./total no. (%)	1/143 (0.7%)	0	–
Hospital outcomes			
Home- no./total no. (%)*	97/182 (53%)	119/178 (67%)	0.009
Acute rehabilitation facility- no./total no. (%)	21/190 (11%)	12/178 (7%)	0.148
Nursing home - no./total no. (%)*	57/190 (30%)	36/178 (20%)	0.031
LTAC- no./total no. (%)	6/190 (3%)	4/178 (2%)	0.152
Length of Stay- median (IQR)	10.3 (4.8–32.5)	8.3 (3.7–19.9)	0.056
Ventilator Days- median (IQR)	12.6 (5.5–27.6)	9.0 (2.9–24.7)	0.152

* Indicates $P < 0.05$; IQR = interquartile range; COPD = chronic obstructive pulmonary disease; SOFA = sequential organ failure assessment; TIA = transient ischemic attack; LTAC = long term acute care hospital.

Results of multivariable ordinal logistic regression analysis for the primary mRS outcome are shown in Table 2. The occurrence of new neurological complications during COVID-19 hospitalization remained a significant independent predictor of worse 6-month mRS scores (adjusted OR 1.98, 95% CI 1.23–3.48, $P = 0.02$). Other significant predictors were older age, worse baseline functional status (as measured by baseline mRS), and longer hospital length of stay (Table 2).

3.3. Secondary outcomes (Barthel Index, NeuroQoL and Return to Work)

Patients with neurological complications were more likely to have impaired activities of daily living as measured by the Barthel Index (53% versus 35% of controls, Chi-squared test $P = 0.002$) and were less likely to return to work (41% versus 64% of controls, Chi-squared test $P = 0.004$; Table 2). Though neurological patients scored worse on the telephone MoCA (median 17 versus 18, Wilcoxon rank-sum test $P = 0.036$), after excluding patients with baseline dementia, there was no difference between groups. Neuro-QoL T-scores for anxiety, depression, fatigue and sleep were also similar between both groups. Hospital readmission occurred in 14% of patients in both groups (Table 3). Overall, persistent dyspnea severe enough to limit normal activity occurred in 35% of patients and did not differ between groups.

In multivariable analyses, neurological complications during hospitalization remained an independent predictor of limited activities of daily living (aOR 0.38, 95% CI 0.20–0.74) and was inversely associated with return to work (aOR 0.31, 95% CI 0.10–0.95; Table 4). Older age, and worse baseline functional status were consistent independent




Fig. 2. Ordinal logistic regression analysis of 6-month modified Rankin scores among patients with and without neurological disorders during hospitalization for COVID-19. (Adjusted odds ratio OR 1.98, 95% confidence interval 1.23–3.48, $P = 0.02$).

Table 2

Predictors of 6-month Modified Rankin Score in multivariable ordinal logistic regression analysis, $N = 382$.

Variable	Adjusted OR (95% CI)	P
Neurological Complication during Hospitalization	1.98 (1.23–3.48)	0.02
Age (per year)	1.02 (1.00–1.04)	0.02
Baseline modified Rankin Score	1.98 (1.61–2.42)	<0.001
Hospital Length of Stay (per day)	1.03 (1.01–1.06)	0.02

OR = Odds Ratio; CI = confidence interval.

Additional Variables tested in the model included: BMI, history of atrial fibrillation, history of dementia, history of stroke, history of seizure, history of venous thromboembolism, diabetes, history of psychiatric illness, history of chronic kidney disease, history of coronary artery disease, worst sequential organ failure assessment score during hospitalization, toxic metabolic encephalopathy during hospitalization, hypoxic-ischemic encephalopathy during hospitalization, acute renal failure during hospitalization, education ≤ 12 years, married versus not, lowest mean arterial blood pressure, use of zinc during hospitalization (all $P > 0.05$).

predictors of worse outcome across a spectrum of other outcome measures. Acute respiratory failure requiring invasive mechanical ventilation was associated with limited ADLs and worse than average sleep, while the interaction of hypotension requiring vasopressors and intubation was associated with worse than average fatigue at 6-months, suggesting a synergistic effect of both hypotension and hypoxia (Table 4).

While many of the outcome metrics (mRS, Barthel, anxiety, depression, fatigue, sleep, hospital readmission, return to work and persistent dyspnea), with the exception of the telephone MOCA, were significantly correlated with one another, correlation coefficients were generally modest, ranging from $Rho = -0.04$ for return to work and anxiety T-scores, to $Rho = 0.497$ for fatigue and sleep T-scores. One exception to this was the Barthel and mRS scores, which were strongly correlated ($Rho = -0.788$, $P < 0.001$, Supplemental Table 3).

4. Discussion

In this prospective study, we found that patients diagnosed with new neurological complications during hospitalization for COVID-19 had a 2-fold increased odds of worse 6-month functional outcome (as measured by the modified Rankin Score) compared to hospitalized COVID-19 patients without neurological complications. Furthermore, over half of these neurologically affected patients could not independently perform some of their basic activities of daily living and 59% of those employed prior to COVID-19 infection were unable to return to

Table 3

Secondary outcomes at 6-months among COVID-19 patients with and without neurological disorders during hospitalization.

	Neurologic COVID-19		COVID-19 Control		P
	Total N	Median, IQR or N (%)	Total N	Median, IQR or N (%)	
Activities of daily living					
Barthel Index	156	95 (70–100)	148	100 (90–100)	0.001
Any abnormal activities of daily living (Barthel < 100)	156	82/156 (53%)	148	52/148 (35%)	0.002
Return to work among those working pre-morbidly	74	30/74 (41%)	80	51/80 (64%)	0.004
Cognitive outcomes					
Telephone MOCA	101	17 (13–19)	114	18 (15–20)	0.044
	90*	18 (15–19)	111*	18 (15–20)	0.24*
Abnormal MOCA (< 18)	101	55 (46%)	114	51 (55%)	0.16
	90*	45 (50%)*	111*	50 (45%)*	0.48*
Neuro quality of life					
Anxiety T-score	137	47.3 (42.1–55.0)	143	48.4 (42.1–54.2)	0.71
Depression T-score	136	45.3 (36.9–51.3)	143	45.6 (36.9–49.8)	0.43
Fatigue T-score	134	45.6 (38.2–54.4)	138	44.7 (39.5–53.3)	0.76
Sleep T-score	135	47.3 (39.1–54.4)	143	45.6 (39.1–51.8)	0.35
Worse than average Anxiety, (T-score > 50)	137	64/137 (47%)	143	79/143 (45%)	0.74
Worse than average Depression, (T-score > 50)	136	40/136 (29%)	143	31/143 (22%)	0.14
Worse than average Fatigue, (T-score > 50)	134	47/134 (35%)	138	51/138 (37%)	0.75
Worse than average Sleep, (T-score > 50)	135	58/135 (43%)	143	47/143 (33%)	0.08
Other					
Hospital Readmission in last 6-months	196	28/196 (14%)	186	26/186 (14%)	0.81
Dyspnea severe enough to limit activity	144	52/144 (36%)	141	49/141 (35%)	0.81

Excluding patients with a history of dementia or memory disorders. IQR = interquartile range; MOCA = Montreal Cognitive Assessment

Table 4

Predictors of 6-month secondary outcomes in multivariable binary logistic regression analysis.

Variable	Adjusted OR (95% CI)	P
Normal ADLs (Barthel Index 100) [^] , N = 304		
Neurological Complication during Hospitalization	0.38 (0.20–0.74)	0.01
Age (per year)	0.96 (0.94–0.99)	0.001
Baseline modified Rankin Score	0.43 (0.32–0.59)	<0.001
History of atrial fibrillation	0.23 (0.06–0.82)	0.02
Intubation	0.28 (0.13–0.60)	0.001
Abnormal Cognition (MOCA \leq 18) [#] , N = 215		
Age (per year)	1.03 (1.01–1.05)	0.01
Race (white vs non-white)	0.41 (0.22–0.78)	0.01
Education > 12 years	0.40 (0.18–0.89)	0.03
History of dementia	4.48 (1.16–17.37)	0.03
Anxiety worse than average (T-score > 50) [†] , N = 280		
Baseline modified Rankin Score	1.25 (1.02–1.54)	0.03
Depression worse than average (T-score > 50) [‡] , N = 279		
Baseline modified Rankin Score	1.27 (1.03–1.57)	0.03
Fatigue worse than average (T-score > 50) [§] , N = 272		
Baseline modified Rankin Score	1.48 (1.16–1.89)	0.001
Hypotension requiring vasopressors and Intubation*	3.83 (1.74–8.43)	0.001
Sleep worse than average (T-score > 50) [§] , N = 278		
Baseline modified Rankin Score	1.37 (1.09–1.72)	0.01
Intubation	2.95 (1.48–5.91)	0.002
Return to work [¶] , N = 154		
Neurological Complication during Hospitalization	0.31 (0.10–0.95)	0.04
Worst SOFA	1.38 (1.03–1.84)	0.03
Hospital Length of Stay (per day)	0.90 (0.84–0.97)	0.01
Race (white vs non-white)	5.03 (1.62–5.59)	0.01

Univariate variables with $P < 0.100$ (see Table S2) were evaluated in multivariable logistic regression analysis for each outcome. Additional variables tested in each model are as below (all $P > 0.05$):

[^] Barthel Index: married versus not, male sex, history of dementia, history of seizure, history of psychiatric illness, history of stroke, history of chronic kidney disease, history of coronary artery disease, worst SOFA score during hospitalization, hypotension requiring vasopressors during hospitalization, lowest mean arterial pressure during hospitalization, toxic metabolic encephalopathy during hospitalization, hypoxic-ischemic encephalopathy during hospitalization, corticosteroid use during hospitalization, the interaction term for hypotension requiring vasopressors and intubation.

[#]Telephone MOCA: neurological complication during hospitalization, baseline modified Rankin score.

* represent interaction term for intubation and hypotension requiring vasopressors; ADLs = activities of daily living; OR = Odds Ratio; CI = confidence interval; SOFA = sequential organ failure assessment.

[†] Anxiety: Neurological complications during hospitalization, age, history of dementia, body mass index.

[‡] Depression: Neurological complications during hospitalization, history of stroke.

[§] Fatigue: Neurological complications during hospitalization, history of chronic kidney disease, history of coronary artery disease, lung severity of illness scale, worst SOFA score during hospitalization, intensive care unit stay, intubation, hypotension requiring vasopressors, lowest mean arterial pressure during hospitalization, corticosteroid use during hospitalization, anticoagulation during hospitalization, hospital length of stay.

[§] Sleep: Neurological complications during hospitalization, lung severity of illness scale, intensive care unit stay, lowest mean arterial pressure during hospitalization, hypotension requiring vasopressors, lowest oxygen saturation during hospitalization, the interaction term for hypotension and intubation, corticosteroid use during hospitalization, anticoagulation during hospitalization, hospital length of stay.

[¶] Return to work: lung severity of illness scale, intubation, hypotension requiring vasopressors, the interaction term for hypotension requiring vasopressors and intubation, intensive care unit stay, lowest oxygen saturation during hospitalization, history of seizure, toxic metabolic encephalopathy

during hospitalization, hypoxic-ischemic encephalopathy during hospitalization, corticosteroid use during hospitalization, anticoagulation during hospitalization, education > 12 years, lowest mean arterial pressure during hospitalization, acute renal failure during hospitalization, zinc use during hospitalization.

work by 6-months. We did not identify significant correlations with return to work and fatigue (Spearman's rho -0.118 , $P = 0.16$), or depression (Spearman's rho -0.152 , $P = 0.07$), suggesting that these factors were not primarily driving employment status. Though return to work metrics may be impacted by unmeasurable pandemic-related economic conditions, patients with neurological complications were still significantly less likely to return to work, even after adjusting for confounders, than patients living in the same metropolitan area without neurological complications. Similarly, while patients with new neurological events had higher baseline levels of dementia, stroke, and seizure, increased odds of worse 6-month functional outcomes persisted after adjusting for these baseline differences, as well as for age and baseline premorbid modified Rankin scores.

Though we hypothesized that patients with neurological disorders would generally have worse long-term outcomes, we found that both groups of patients had high rates of cognitive impairment approaching or exceeding 50% at 6-months. While we did not compare our patients to non-COVID controls, the estimated prevalence of mild cognitive impairment in the general community among patients aged 65–69 years (the median age of our population) is only 8.4% [29] and the prevalence of dementia is <1% [30]. Notably, we did not find a correlation between depression and cognition scores, suggesting that depression alone is not the cause of cognitive deficits. Neuropsychiatric symptom burden was also substantial, with nearly two-thirds of all patients reporting worse than average anxiety, depression, fatigue or sleep disorders. Because we used T-scores for Neuro-QoL metrics, these findings represent abnormalities compared to reference populations. Though we identified significant relationships between most outcome measures and self-reported persistent dyspnea, the association was weak and it does not seem that dyspnea alone can fully account for the levels of disability or cognitive impairment that we measured.

Strengths of our study include its prospective ascertainment of data beginning at the time of index hospitalization, initial neurological diagnoses by board-certified neurologists [11], a propensity-score matched control group and a multi-domain outcome battery. This is the first study, to our knowledge to prospectively assess long-term neurological function and cognitive outcomes among COVID-19 hospital survivors in a standardized fashion. Other studies have presented short-term outcomes between 2 weeks and 2 months from COVID-19 symptom onset, but neither used formal assessments of fatigue, mood, cognition or functional status [31,32]. In one study of outpatients diagnosed with COVID-19, reports of protracted symptoms during the subacute phase (14–21 days) included persistent fatigue in 35%, persistent loss of taste/smell in 20% and confusion in 20% [32]. Another study in a hospitalized COVID-19 cohort found that 87% of patients had at least one lingering COVID-19 symptom in a mean of 60 days after initial COVID-19 symptom onset, with the most common long-term symptoms being fatigue (53%) and dyspnea (43%) [31]. In a large, 6-month study of a COVID-19 cohort from Wuhan, China [22], fatigue or muscle weakness was reported in 63%, and sleep difficulties in 23%, however, these metrics were not assessed using a standardized battery and it is unclear how these rates compare to a reference population. This study also identified anxiety or depression in 23% based on the EuroQol five-dimension five-level questionnaire, but this metric does not differentiate anxiety and depression. This study also excluded some of the sickest patients such as those with underlying dementia, psychiatric illness, hospital readmission, nursing home or facility patients and those physically unable to return for an in-person follow-up. This may explain the higher rates of anxiety (46% of patients), and depression (25%) that we observed.

We identified neurological complications during index COVID-19 hospitalization, age, and worse premorbid baseline functional status as independent predictors of poor outcomes, however, these risk factors are not readily modifiable. Invasive mechanical ventilation and hypotension requiring vasopressors were associated with worse activities of daily living, fatigue and sleep. These variables may be potentially modifiable by medications and therapeutics that were not available early in the pandemic. While we anticipated an association between the severity of lung injury, hypoxia and worse cognitive outcomes based on prior ARDS studies [33] and neuropathological findings of hypoxic brain injury in COVID-19 autopsy specimens [34–38], we did not find a significant relationship. One possibility is that the telephone MOCA may not be sensitive enough to detect certain types of cognitive impairment. We used this tool because it is validated for phone interview and would allow us to gather data on patients that would not otherwise be able to complete follow-up in person due to pandemic related restrictions. Another possibility is that we were unable to fully capture the duration and severity of hypoxemia burden using stochastic measures of the lowest oxygen saturation or the lung injury severity scale [22]. Furthermore, there is likely an interaction between hypoxemia and hypotension that compounds the risk of cognitive deficits, however, we only identified a significant effect of the interaction of intubation and hypotension requiring vasopressors on the outcome of fatigue. The degree and duration of hypoxemia and/or hypotension required to cause permanent brain injury may vary from patient to patient depending on the presence of flow-limiting extra- or intracranial vessel stenosis, carbon dioxide levels, the integrity of cerebral autoregulation, prior ischemic damage, and the degree of brain metabolic activity and blood flow coupling. Big data studies evaluating oxygen and blood pressure levels are needed to evaluate these associations further.

We also documented a high rate of readmission (14%) in both the neurological patients and controls compared to other studies, which reported rates as low as 1% at 6-months [22] and 3.6% at 14-days post discharge [39]. However, the first study excluded patients for whom follow-up would be difficult (including those readmitted to a hospital for underlying diseases) [22] and the other looked at short-term readmissions within its own hospital system, not accounting for readmissions that could occur outside of its network [39]. Because our readmission data came directly from patients or their surrogates, we were able to capture readmissions across different hospital systems. It is likely that limited access to outpatient follow-up during the New York COVID-19 surge may have contributed to this high readmission rate. Systematic video and phone follow-up early after discharge may help mitigate readmission risk.

There are limitations to our work. First, though all patients completed the mRS evaluation, the sickest patients were unable to complete other metrics due to limited function. Thus, secondary outcomes may actually be worse than what we were able to measure. Additionally, family members of patients who did poorly may be less motivated to participate in research. Second, certain outcomes may be confounded by unmeasured factors. For example, return to work may be impacted by the current economic environment. Anxiety, depression, fatigue and sleep may be similarly impacted by unmeasured societal, economic and environmental pandemic-associated factors. Comparing COVID-19 patients to similar community members without COVID-19 would help quantify the impact of some of these unmeasured factors. Third, though we identified high rates of disability among both neurological COVID-19 patients and controls, this study was not designed to determine whether the deficits measured by these metrics are static or represent ongoing injury as suggested by some “long-hauler” and post-COVID literature [40]. Since cognitive impairment and mood abnormalities occur in over 50% of ARDS survivors [41], it is possible that the level of disability we are documenting is not specific to SARS-CoV-2, but rather a result of factors related to critical viral illness. Additional one-year follow-up in this cohort may help clarify the trajectory of recovery. Fourth, while we were able to adjust for a variety of past neurological

diagnoses in multivariable analyses, we had limited data on specific psychiatric diagnoses (e.g. depression, bipolar disorder, thought disorder). We did adjust for a conglomerate variable of “past psychiatric history”, but further differentiation may have provided insights into analyses of NeuroQoL outcomes. Fifth, the telephone MOCA is meant to screen for cognitive impairment, but more extensive neuropsychological testing is needed to identify specific domains of cognitive abnormality. While we did adjust for years of education when scoring the telephone MOCA, other societal factors may impact scores [27]. Sixth, we did not obtain information regarding therapeutic interventions that may have modulated outcomes. We are currently studying the impact of both conventional and alternative treatments on functional, cognitive and NeuroQoL metrics at 1-year follow-up post-hospitalization for COVID. Finally, while we did find a small, yet significant relationship between ongoing severe dyspnea and other outcome metrics, we did not use a standardized measure of dyspnea because we felt that a longer survey would lead to participant fatigue and incomplete responses. Further investigation of the impact of long-term pulmonary sequelae on neurological outcomes is warranted.

5. Conclusions

Over 90% of COVID-19 patients in this cohort had at least one abnormal outcome metric at 6-months: 56% of patients had limited activities of daily living, 50% had abnormal cognition, 62% had worse than average anxiety, depression, fatigue or sleep and 47% of those working pre-morbidly were unable to return to work. Patients with neurological complications during their index COVID-19 admission had significantly worse functional outcomes as measured by the mRS and Barthel scales, and were less likely to return to work, even after accounting for other premorbid factors. The frequency and severity of functional, cognitive and mood abnormalities among COVID-19 hospital survivors— with or without neurological complications— should factor into educational and preventive efforts directed at patients, physicians and the general public.

Disclosures

NIH/NIA grant 3P30AG066512-01S1 to Thomas Wisniewski, Jennifer Frontera and Laura Balcer and NIH/NINDS grant 3U24NS11384401S1 to Andrea Troxel, Eva Petkova, Jennifer Frontera, Sharon Meropol and Shadi Yaghi.

Data sharing

De-identified data will be made available to qualified investigators upon written request to the corresponding author.

Acknowledgments

We thank the patients and families who agreed to participate in this study.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jns.2021.117486>.

References

- [1] S. Agarwal, E. Scher, N. Rossan-Ragunath, et al., Acute stroke care in a new York City comprehensive stroke center during the COVID-19 pandemic, *J. Stroke Cerebrovasc. Dis.* 29 (9) (2020) 105068.
- [2] M.A. Ellul, L. Benjamin, B. Singh, et al., Neurological associations of COVID-19, *Lancet Neurol.* 19 (9) (2020) 767–783.

- [3] E.M. Liotta, A. Batra, J.R. Clark, et al., Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients, *Ann. Clin. Transl. Neurol.* 7 (11) (2020 Nov) 2221–2230.
- [4] K.R. Melmed, M. Cao, S. Dogra, et al., Risk factors for intracerebral hemorrhage in patients with COVID-19, *J. Thromb. Thrombolysis* 51 (4) (2021 May) 953–960.
- [5] S. Kremer, F. Lersy, M. Anheim, et al., Neurologic and neuroimaging findings in patients with COVID-19: a retrospective multicenter study, *Neurology*. 95 (13) (2020) e1868–e1882.
- [6] L. Mao, H. Jin, M. Wang, et al., Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China, *JAMA Neurol.* 77 (6) (2020) 683–690.
- [7] C.M. Romero-Sanchez, I. Diaz-Maroto, E. Fernandez-Diaz, et al., Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOV registry, *Neurology*. 95 (8) (2020) e1060–e1070.
- [8] J. Helms, S. Kremer, H. Merdji, et al., Neurologic features in severe SARS-CoV-2 infection, *N. Engl. J. Med.* 382 (23) (2020) 2268–2270.
- [9] S. Yaghi, K. Ishida, J. Torres, et al., SARS-CoV-2 and stroke in a New York healthcare system, *Stroke*. 51 (7) (2020) 2002–2011.
- [10] WHO Summary of ICD Coding for COVID-19. <http://www.whofig.org.za/SummaryICDcoding.pdf>. Accessed 4/15/2021.
- [11] J.A. Frontera, S. Sabadia, R. Lalchan, et al., A prospective study of neurologic disorders in hospitalized COVID-19 patients in New York City, *Neurology*. 96 (4) (2021 Jan) e575–e586.
- [12] A.R. Tunkel, C.A. Glaser, K.C. Bloch, et al., The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America, *Clin. Infect. Dis.* 47 (3) (2008) 303–327.
- [13] A.R. Tunkel, B.J. Hartman, S.L. Kaplan, et al., Practice guidelines for the management of bacterial meningitis, *Clin. Infect. Dis.* 39 (9) (2004) 1267–1284.
- [14] A. Venkatesan, A.R. Tunkel, K.C. Bloch, et al., Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium, *Clin. Infect. Dis.* 57 (8) (2013) 1114–1128.
- [15] A.R. Tunkel, R. Hasbun, A. Bhimraj, et al., 2017 Infectious diseases society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis, *Clin. Infect. Dis.* 64 (6) (2017) e34–e65.
- [16] T.F. Scott, E.M. Frohman, J. De Seze, et al., Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the therapeutics and technology assessment subcommittee of the American Academy of neurology, *Neurology*. 77 (24) (2011) 2128–2134.
- [17] R.L. Sacco, S.E. Kasner, J.P. Broderick, et al., An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association, *Stroke*. 44 (7) (2013) 2064–2089.
- [18] C. Fokke, B. van den Berg, J. Drenth, C. Walgaard, P.A. van Doorn, B.C. Jacobs, Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria, *Brain J. Neurol.* 137 (Pt 1) (2014) 33–43.
- [19] J. Kalita, U.K. Misra, M. Das, Neurophysiological criteria in the diagnosis of different clinical types of Guillain-Barre syndrome, *J. Neurol. Neurosurg. Psychiatry* 79 (3) (2008) 289–293.
- [20] J.J. Sejvar, K.S. Kohl, J. Gidudu, et al., Guillain-Barre syndrome and fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data, *Vaccine*. 29 (3) (2011) 599–612.
- [21] J. Frontera, S. Mainali, E.L. Fink, et al., Global consortium study of neurological dysfunction in COVID-19 (GCS-NeuroCOVID): study design and rationale, *Neurocrit. Care*. 33 (1) (2020) 25–34.
- [22] C. Huang, L. Huang, Y. Wang, et al., 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study, *Lancet*. 397 (10270) (2021 Jan) 220–232.
- [23] J.C. van Swieten, P.J. Koudstaal, M.C. Visser, H.J. Schouten, J. van Gijn, Interobserver agreement for the assessment of handicap in stroke patients, *Stroke*. 19 (5) (1988) 604–607.
- [24] F.I. Mahoney, D.W. Barthel, Functional evaluation: the Barthel index, *Md. State. Med. J.* 14 (1965) 61–65.
- [25] S.T. Pendlebury, S.J. Welch, F.C. Cuthbertson, J. Mariz, Z. Mehta, P.M. Rothwell, Telephone assessment of cognition after transient ischemic attack and stroke: modified telephone interview of cognitive status and telephone montreal cognitive assessment versus face-to-face montreal cognitive assessment and neuropsychological battery, *Stroke*. 44 (1) (2013) 227–229.
- [26] D. Cella, J.S. Lai, C.J. Nowinski, et al., Neuro-QoL: brief measures of health-related quality of life for clinical research in neurology, *Neurology*. 78 (23) (2012) 1860–1867.
- [27] H.C. Rossetti, L.H. Lacritz, C.M. Cullum, M.F. Weiner, Normative data for the Montreal cognitive assessment (MoCA) in a population-based sample, *Neurology*. 77 (13) (2011) 1272–1275.
- [28] Neuro-QoL, Neuro-QoL Reference Populations. <https://www.healthmeasures.net/score-and-interpret/interpret-scores/neuro-qol/reference-populations>, 2021.
- [29] R.C. Petersen, O. Lopez, M.J. Armstrong, et al., Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology, *Neurology*. 90 (3) (2018) 126–135.
- [30] W.M. van der Flier, P. Scheltens, Epidemiology and risk factors of dementia, *J. Neurol. Neurosurg. Psychiatry* 76 (Suppl. 5) (2005) v2–v7.
- [31] A. Carfi, R. Bernabei, F. Landi, Gemelli Against C-P-ACSG, Persistent symptoms in patients after acute COVID-19, *JAMA*. 324 (6) (2020) 603–605.
- [32] M.W. Tenforde, S.S. Kim, C.J. Lindsell, et al., Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020, *MMWR Morb. Mortal. Wkly Rep.* 69 (30) (2020) 993–998.
- [33] P.P. Pandharipande, T.D. Girard, J.C. Jackson, et al., Long-term cognitive impairment after critical illness, *N. Engl. J. Med.* 369 (14) (2013) 1306–1316.
- [34] M.H. Lee, D.P. Perl, G. Nair, et al., Microvascular injury in the brains of patients with Covid-19, *N. Engl. J. Med.* 384 (5) (2021 Feb) 481–483.
- [35] I.H. Solomon, E. Normandin, S. Bhattacharyya, et al., Neuropathological features of Covid-19, *N. Engl. J. Med.* 383 (10) (2020) 989–992.
- [36] B. Hanley, K.N. Nares, C. Roufosse, et al., Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study, *Lancet Microbe*. 1 (6) (2020) e245–e253.
- [37] J. Kantonen, S. Mahzabin, M.I. Mayranpaa, et al., Neuropathologic features of four autopsied COVID-19 patients, *Brain Pathol.* 30 (6) (2020) 1012–1016.
- [38] N. Deigendesch, L. Sironi, M. Kutza, et al., Correlates of critical illness-related encephalopathy predominate postmortem COVID-19 neuropathology, *Acta Neuropathol.* 140 (4) (2020) 583–586.
- [39] S.S. Somani, F. Richter, V. Fuster, et al., Characterization of patients who return to hospital following discharge from hospitalization for COVID-19, *J. Gen. Intern. Med.* 35 (10) (2020) 2838–2844.
- [40] V.O. Puntmann, M.L. Carerj, I. Wieters, et al., Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19), *JAMA Cardiol.* 5 (11) (2020) 1265–1273.
- [41] P. Riordan, M. Stika, J. Goldberg, M. Drzewiecki, COVID-19 and clinical neuropsychology: a review of neuropsychological literature on acute and chronic pulmonary disease, *Clin. Neuropsychol.* 34 (7–8) (2020) 1480–1497.